List of Hemady drug patents

Hemady is owned by Dexcel Pharma.

Hemady contains Dexamethasone.

Hemady has a total of 2 drug patents out of which 0 drug patents have expired.

Hemady was authorised for market use on 03 October, 2019.

Hemady is available in tablet;oral dosage forms.

Hemady can be used as a method of treating adults with multiple myeloma using dexamethasone in combination with an anti-myeloma product.

The generics of Hemady are possible to be released after 18 December, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537585 DEXCEL PHARMA Compositions comprising dexamethasone
Dec, 2037

(14 years from now)

US11304961 DEXCEL PHARMA Compositions comprising dexamethasone
Dec, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 3, 2026

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 03 October, 2019

Treatment: A method of treating adults with multiple myeloma using dexamethasone in combination with an anti-myeloma product

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in